BTK Inhibitors Mantle Cell Lymphoma: How they work and what to expect
• BTK inhibitors are a type of targeted therapy for mantle cell lymphoma that works by blocking a specific enzyme, BTK, which is crucial for the cancer cells’ survival and spread. This interference helps to prevent the cancer cells from multiplying and anchoring themselves in the body.
• These inhibitors are used in various stages of mantle cell lymphoma treatment, including as a first-line option for some individuals and as a second or third-line treatment for those whose cancer has returned or is difficult to treat. While effective, they may leave behind minimal residual disease.
• Compared to traditional chemotherapy and stem cell transplants, BTK inhibitors offer the convenience of at-home oral administration and generally have fewer severe side effects. However, they are not suitable for everyone, and treatment decisions are based on individual health, age, and disease stage.
Mantle cell lymphoma (MCL) is a cancer affecting the lymphatic system. As a rare type of B-cell non-Hodgkin lymphoma, it develops in the mantle zone of lymph nodes from immune cells called B lymphocytes.
MCL makes up approximately
While a combination of chemotherapy and immunotherapy (chemoimmunotherapy) remains the standard treatment for MCL, targeted therapies are also available. For some people, doctors may recommend Bruton’s tyrosine kinase (BTK) inhibitors, which are targeted therapies that block the enzyme BTK.
This article takes a closer look at BTK inhibitors and their role in mantle cell lymphoma.
Targeted therapies in cancer treatment work by interfering with a specific process necessary for a cancer’s growth, survival, or spread.
BTK inhibitors in MCL target the enzyme BTK. In healthy B-cells, BTK regulates the B-cell receptor signaling that is essential to a B-cell’s function, movement, and lifespan.
In MCL, BTK signaling becomes overactive. It signals cancerous B-cells to stay alive longer and encourages them to divide and make copies of themselves. It also helps MCL cells stay anchored in lymph nodes and other locations favorable to their survival.
By blocking BTK, BTK inhibitors cut off the cancer cell’s survival pathway. MCL relies heavily on BTK signaling. Without it, the cells don’t multiply as effectively and can detach from their safe environments.
BTK inhibitors are a first-line therapy for some people and a second- or third-line therapy for others.
When they were first approved for the treatment of MCL, BTK inhibitors were intended for people with difficult-to-treat (refractory) MCL or those who experienced relapse.
This initial focus arose because clinical trials at the time primarily enrolled individuals who had already received traditional care. The scope of treatment eventually expanded as researchers continued to demonstrate the safety and effectiveness of BTK inhibitors.
Now, BTK inhibitors are treatment options for relapsed and refractory MCL, but they’re also first-line options for certain people who:
BTK inhibitors have been proven safe and effective for treating MCL in specific people, but they are not for everyone.
Doctors still favor traditional chemoimmunotherapy and stem cell transplant for people who are younger and otherwise healthy. These treatments are considered intensive, but they offer a chance at a functional cure.
BTK inhibitors are highly effective and can be taken at home, but they can leave behind minimal residual disease. This means very small amounts of MCL cells can remain after treatment, even if diagnostic imaging appears normal, lymph nodes have shrunk, and clinical symptoms have disappeared.
While they’re still used as a first-line treatment for certain people, BTK inhibitors are primarily used to control MCL long-term when chemoimmunotherapy and transplant are not enough or appropriate.
BTK inhibitors can be taken at home, by mouth, once or twice daily. Most people stay on these medications until they experience disease progression or medication toxicity.
Most cancer therapies can cause side effects. BTK inhibitors are effective at disrupting cancer cell signaling, but they can also affect the signaling of healthy B-cells.
First-generation BTK inhibitors, such as ibrutinib, are less selective than newer BTK inhibitors. They can block other enzymes in the body, increasing the risk of specific side effects.
First-generation BTK inhibitors are associated with a higher risk of cardiovascular events, such as high blood pressure and irregular heartbeat.
Convenience is one of the main benefits of BTK inhibitors.
They can be taken at home, by mouth. Chemoimmunotherapy and stem cell transplantation are more invasive. They require multiple doctor appointments, treatment cycles in clinical settings, monitoring tests, and hospital admission.
BTK inhibitors also tend to have fewer significant side effects compared to standard MCL therapies.
Not everyone is a candidate for BTK inhibitor therapy. A person’s age, overall health, MCL stage, and personal preferences can affect treatment choices.
BTK inhibitors are a type of targeted cancer therapy. They work in MCL by disrupting the survival pathway cancer cells rely on for growth and spread.
Not everyone is a candidate for BTK inhibitor therapy. Chemotherapy and stem cell transplants are still the primary treatment for this type of cancer in people who are younger and otherwise fit. When standard treatments are not appropriate or are not effective enough, doctors consider using BTK inhibitors as a first-line option.